Back to News
Market Impact: 0.15
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Source: GlobeNewswire
Healthcare & BiotechManagement & Governance
Dr. Spiegel has been appointed to a leadership role, bringing decades of global clinical-development, regulatory and oncology experience. Her prior Chief Medical Officer positions at Schering-Plough and PTC Therapeutics may strengthen the company's clinical and regulatory capabilities, though no financial terms, trial data, or operating guidance were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
PTCT0.10
More News
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Why is Xenon Pharmaceuticals stock plunging today?
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- ‘We need sufficient means of control before it is all too late’: King Charles III warns AI players on concerns of ‘existential dangers’